Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants

  1. Amparo L. Figueroa
  2. Bethany Girard
  3. Darin K Edwards
  4. Arshan Nasir
  5. Kimball Johnson
  6. Steven Hack
  7. Xin Cao
  8. Elizabeth de Windt
  9. Veronica Urdaneta
  10. Frances Priddy
  11. Rituparna Das
  12. David C Montefiori
  13. Spyros Chalkias
Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

In this ongoing, open-label phase 3b/4 study, JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines elicited robust neutralizing antibody responses against vaccine-matched variants and cross-neutralized currently circulating JN.1 subvariants (KP.3.1.1, XEC, LP.8.1) in adults with previous COVID-19 mRNA vaccination, with reduced cross-neutralization observed against all subvariants tested. No safety concerns were identified.

Article activity feed

  1. Version published to 10.1101/2025.05.02.25325954v2 on medRxiv
  2. Version published to 10.1101/2025.05.02.25325954v1 on medRxiv